Pharmaceutical Technology11 小时
CCAR-168 by AbelZeta for Lupus Nephritis: Likelihood of Approval
CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Pharmaceutical Technology3 小时
GCC-4001 by Artiva Biotherapeutics for Rheumatoid Arthritis: Likelihood of Approval
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.
Geode Capital Management LLC Raises Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)
Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 12.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,094 ...